Physician profile
Hershel Eli Dobkin
NPI 1205330826
$44,094.04
in general payments reported to CMS, 2019-2025
35 companies · $30K in 2025
The $30K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.88 · 2020: $14.33 · 2021: $365 · 2022: $1,991 · 2023: $4,232 · 2024: $7,290 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Food and Beverage: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,900 · Education: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,369.00 |
| Food and Beverage | $14,982.04 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,900.00 |
| Education | $458.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $20,037.21 | 2022-2025 | Sotyktu, Cobenfy |
| Pfizer INC. | $5,652.99 | 2022-2025 | |
| Incyte Corporation | $3,567.20 | 2021-2025 | Opzelura |
| Abbvie INC. | $2,990.03 | 2021-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $1,567.94 | 2022-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $1,430.90 | 2023-2025 | Zoryve |
| Ucb, INC. | $1,061.56 | 2022-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $962.97 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $946.97 | 2023-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $792.42 | 2022-2025 | Nemluvio, Epsolay, Aklief |
| Novartis Pharmaceuticals Corporation | $739.72 | 2022-2025 | |
| Amgen INC. | $603.75 | 2022-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $587.37 | 2022-2024 | Vtama |
| Lilly USA, LLC | $545.84 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Medimetriks Pharmaceuticals, INC. | $507.64 | 2023-2024 | Neuac, Ketodan, Neo-Synalar |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $383.68 | 2025 | Vtama, Nexplanon, Hadlima |
| Journey Medical Corporation | $305.41 | 2022-2023 | |
| Leo Pharma INC. | $191.87 | 2023-2025 | Adbry, Anzupgo |
| Epi Health, LLC | $188.84 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $185.69 | 2023-2024 | Siliq, Arazlo, Cabtreo |
| Sun Pharmaceutical Industries INC. | $140.86 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Mayne Pharma Commercial LLC | $123.79 | 2022-2025 | |
| Verrica Pharmaceuticals INC. | $90.98 | 2023-2025 | Ycanth |
| Biofrontera INC. | $82.18 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Celgene Corporation | $79.94 | 2024 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $64.99 | 2021 | |
| Kyowa Kirin, INC. | $57.43 | 2023-2025 | Poteligeo |
| Strata Skin Sciences, INC. | $45.46 | 2023 | Xtrac |
| Genentech USA, INC. | $35.22 | 2023-2024 | Erivedge, Xolair |
| Botanix Sb INC | $32.30 | 2025 | Sofdra |
| Johnson & Johnson Health Care Systems INC. | $28.71 | 2024 | Tremfya |
| Mallinckrodt Hospital Products INC. | $23.72 | 2025 | Acthar |
| Convatec INC. | $22.81 | 2025 | |
| Organogenesis INC. | $12.75 | 2023 | Puraply |
| Janssen Scientific Affairs, LLC | $2.90 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hershel Dobkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.